BMI-Adjusted Grip Strength and Sarcopenia in Prediabetes - Summary - MDSpire

BMI-Adjusted Grip Strength and Sarcopenia in Prediabetes

Researchers report 8% prevalence of probable sarcopenia and a 96.4% specificity cutoff for BMI-adjusted grip strength.

  • By

  • Kathryn Wighton

  • April 20, 2026

  • 3 min

Share

Objective:

To evaluate the discriminatory ability of relative handgrip strength (RHGS) in identifying probable sarcopenia in adults with prediabetes.

Approach:
    Key Findings:
    • Probable sarcopenia was identified in 8% of patients.
    • Mean handgrip strength was 28.7 kg in patients without sarcopenia vs 21.1 kg in those with sarcopenia.
    • Mean RHGS was 1.17 in patients without sarcopenia vs 0.92 in those with sarcopenia.
    • ROC analysis showed RHGS had a corrected area under the curve of 0.867, with an optimal cutoff of 0.835 yielding 66.7% sensitivity and 96.4% specificity.
    • Lower RHGS was associated with adverse metabolic parameters and lower vitamin D levels.
    Interpretation:

    RHGS demonstrated strong discriminatory performance in identifying low handgrip strength-defined probable sarcopenia, suggesting its potential as a practical screening tool in prediabetic populations.

    Limitations:
    • Cross-sectional design limits causal inference.
    • Single-center study may affect generalizability.
    • Probable sarcopenia defined without direct muscle mass assessment.
    • Wide confidence intervals for some variables due to limited sample size.
    Conclusion:

    RHGS may serve as an effective screening tool for probable sarcopenia in prediabetic individuals, warranting further investigation.

    Sources:

Original Source(s)

BMI-Adjusted Grip Strength and Sarcopenia in Prediabetes

  • by Kathryn Wighton

  • April 20, 2026

Related Content

How Quickly Are Patients Reaching Quadruple HFrEF Therapy?

Delays in initiating guideline-directed quadruple therapy may increase early clinical risk in heart failure with reduced ejection fraction.

Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.